The United States drug discovery market is predicted to record a CAGR of 6.26% during the forecast period, 2022-2028, projecting revenue of $32933.52 million by 2028.

To know more about this report, request a free sample copy

The rising use of self-administering drugs and the growing awareness about treatment and diagnosis globally drive market growth. Also, as per the World Health Organization (WHO), enhanced healthcare systems and medical treatment have enabled high survival rates from injuries and diseases in the last decade. Additionally, the prevalence of medical conditions and diseases like respiratory diseases, strokes, neurological disorders, cancer, diabetes, and cardiovascular diseases, has significantly increased. This has raised the demand for drug delivery, which influences the growth of the market studied.

Further, recent innovations and developments in drug delivery systems like transdermal patches, injectable drug delivery, and pulmonary systems offer growth opportunities. Also, the pandemic has encouraged the expansion of the drug discovery market, given the impediments witnessed like medication unavailability and the lack of healthcare infrastructure and effective treatment. in addition, the surging lifestyle-oriented diseases, technological advancements, the growing demand for specialty medicines, the rising elderly population, the increasing healthcare, and R&D expenditure contribute to market growth.

The United States drug discovery market segmentation includes the analysis of technology, service, drug type, and end-user. The technology category is further sub-segmented into pharmacogenomics and pharmacogenetics, high throughput screening, metabolomics, nanotechnology, combinatorial chemistry, biochips, spectroscopy, bioinformatics, and other technologies. Of these, high throughput screening, nanotechnology, and spectroscopy are further explained.

High throughput screening aids in automated testing of large numbers of biological or chemical compounds for a specific biological target. It is primarily used in the pharmaceutical industry, wherein many molecules’ biochemical or biological activities can be tested using automation and robotics. The automation facilitates the rapid conduct of a large number of pharmacological, genetic, or chemical tests on drug-like compounds. It also accelerates the assaying by testing many potential biological modulators.

Nanotechnology is the development of innovative research and technology at the macromolecular, molecular, and atomic levels with controlled manipulation. In addition, it offers innovative solutions, offering researchers enhanced data quality, analytical capacity, and less consumption of less sample volume in screening and storing tissue, cell, and molecular libraries. Further, it plays an essential role in improving diagnostic methods and developing better drug delivery systems and drug formulations for disease therapy.

Spectroscopy is the study of the emission and absorption of light and other radiations by matter. NMR (nuclear magnetic resonance) is a spectroscopy technique used by biochemists and chemists to investigate organic molecules’ properties. NMR can determine molecular conformation in solutions once the basic structure is known. Moreover, spectroscopy tests can provide information about the presence of chemical compounds and elements.

Some of the major companies in the United States drug discovery market include Agilent Technologies Inc, Johnson & Johnson, Pfizer Inc, Merck & Co Inc, etc.

Merck & Co Inc is a biopharmaceutical company that offers vaccines and medicines for several diseases. It majorly sells pharmaceutical products to drug wholesalers, government agencies, hospitals, and managed healthcare providers like pharmacy benefit managers and health maintenance organizations. Human health vaccine products entail preventive adult, adolescent, and pediatric vaccines. The company has its headquarters in Kenilworth, NJ.

One of its key products, KEYTRUDA®, is indicated for treating patients with metastatic on unresectable melanoma. It is also indicated for the adjuvant treatment of pediatric and adult patients with Stage III, IIC, or IIB melanoma.

Report Synopsis

To request a free sample copy of this report, please complete the form below:

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.